Robert Dichmann

Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial

Charles S. Fuchs, Kohei Shitara, Maria Di Bartolomeo et al. · The Lancet Oncology · 2019 · 276 citations · Full text

First-line Therapy, Gastrointestinal Oncology, Medicine +6

Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: the CONTROL trial

CH Barcenas, Sara A. Hurvitz, Jack A. Di Palma et al. · Annals of Oncology · 2020 · 102 citations · Full text

Replacement of bortezomib with carfilzomib for multiple myeloma patients progressing from bortezomib combination therapy

James R. Berenson, James Hilger, Ori Yellin et al. · Leukemia · 2014 · 76 citations · Full text

Ascorbic Acid, Hematological Malignancy, Oncology +13

Pathologic and molecular responses to neoadjuvant trastuzumab and/or lapatinib from a phase II randomized trial in HER2-positive breast cancer (TRIO-US B07)

Sara A. Hurvitz, Jennifer L. Caswell‐Jin, Katherine McNamara et al. · Nature Communications · 2020 · 63 citations · Full text

Final Results of a Phase II Trial Evaluating Trastuzumab and Bevacizumab as First Line Treatment of HER2-Amplified Advanced Breast Cancer.

Sara A. Hurvitz, Mark D. Pegram, L. S. Lin et al. · Cancer Research · 2009 · 54 citations

First Line Treatment, Phase Ii Testing, Breast Oncology +12